1999 European Regional Conference Proceeding
May 12 - 16, 1999
| Conference: | 1999 European Regional Conference |
|---|---|
| Title: | V2 vasopressin receptor dysfunction in patients with nephrogenic diabetes insipidus is caused by different molecular mechanisms |
| Authors: | Schulz, Angela; Pasel, Katharina; Volk, HD; Timmermann, Kirsten; Hoeltzenbein, Maria; Jaaskelainen, Jarmo; Gudermann, Thomas; Filler, M.D., Ph.D., FRCPC, Guido; Schoneberg, Torsten |
| Institutions: | University of Leipzig, Institut fur Pharmakologie, Padiatrische Nephrologie, Institut fur Humangenetik, Kuopio University Hospital, Children's Hospital of Eastern Ontario |
Schulz et al., identified three new V2 vasopressin receptor (AVPR2) gene mutations that result in nephrogenic diabetes insipidus (NDI). Two of the mutations, I46K and I130F, could not travel to the cell surface where they must be for proper function. Mutation F105V is able to get to the cell surface, but once there, it is unable to bind with the antidiuretic hormone, vasopressin (VP) with the required high degree of affinity.
The researchers report on one NDI case that resulted from the deletion of the entire AVPR2 gene from the X chromosome. In addition, most of the C1 gene locus on the X chromosome was also missing. The C1 gene encodes for a protein (rhoGAP C1) that is preferentially expressed in white blood cells. The biological function of the rhoGAP C1 protein is poorly understood. Though the researchers extensively analyzed the patient over a 16-year period, they found no related pathology. This led the researchers to conclude that the rhoGAP C1 protein is not essential for normal development in the human. They suggest that the loss of rhoGAP C1 function is compensated by other members of the GAP family and does not require a special therapeutic management of NDI patients with this additional defect.



